|会社名||Esperion Therapeutics Inc (New) （エスペリオン・セラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 エスペリオン・セラピューティクス（Esperion Therapeutics Inc.）は脂質管理会社である。同社は低密度リポタンパク質コレステロール（LDL-C）上昇患者の治療用の1日に1回の経口療法の開発・商業化に焦点を当てた後期の製薬会社である。標的とする作用機序を有するベムドエイド酸は、経口投与が可能な1日1回のアデノシン三リン酸（ATP） - クエン酸リアーゼ（ACL）阻害剤であり、コレステロール生合成を低下させ、LDL- LDL受容体を調節するが、筋肉関連の副作用の可能性が低下する。単独療法としてのベムドエ酸に加えて、同社は、認可された非スタチン系の経口LDL-C降下療法であるエゼチミブと一定用量の組み合わせで、ベムドエ酸を開発中である。 エスペリオン・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。高コレステロ―ル血症及び、その他の心臓代謝リスクマ―カ―を有する患者の治療のため、低比重リポタンパクコレステロ―ル濃度を低下させる治療法の開発、商業化に従事。経口治療薬と小分子治療薬を開発する。本社はミシガン州。 Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.|
|本社所在地||3891 Ranchero Drive Suite 150 Ann Arbor MI 48108 USA|
|代表者氏名||Timothy M. Mayleben ティモシー・M・メレイベン|
|代表者役職名||President Chief Executive Officer Director 社長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Esperion Therapeutics Inc revenues was not reported. Net loss increased 10% to $91.9M. Higher net loss reflects Research and development increase of 9% to $80.5M (expense) General and administrative increase of 24% to $12.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$3.72 to -$3.44.|
Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) 2021/10/26 00:22:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) appeared first on Stocks Equity .
Analysts Expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post -$2.86 EPS 2021/10/25 23:26:41 Dakota Financial News
Wall Street brokerages forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will report ($2.86) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Esperion Therapeutics earnings. The lowest EPS estimate is ($3.05) and the highest is ($2.63). Esperion Therapeutics reported earnings of ($3.07) per share in the same quarter 
Zacks: Analysts Anticipate Esperion Therapeutics, Inc. (NASDAQ:ESPR) Will Announce Quarterly Sales of $12.31 Million 2021/10/25 23:26:41 Transcript Daily
Wall Street analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report sales of $12.31 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Esperion Therapeutics earnings, with the highest sales estimate coming in at $13.00 million and the lowest estimate coming in at $11.23 million. Esperion Therapeutics posted sales 
SG Americas Securities LLC Cuts Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) 2021/10/23 09:26:41 Dakota Financial News
SG Americas Securities LLC lessened its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 14.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,844 shares of the biopharmaceutical companys stock after selling 2,422 shares during the period. SG Americas 
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Credit Suisse Group to Neutral 2021/10/22 06:20:41 Dakota Financial News
Credit Suisse Group lowered shares of Esperion Therapeutics (NASDAQ:ESPR) from an outperform rating to a neutral rating in a report released on Monday, PriceTargets.com reports. The firm currently has $11.00 price target on the biopharmaceutical companys stock, down from their previous price target of $28.00. Several other equities analysts also recently issued reports on the 
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street 2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
Esperion Therapeutics Inc. Shares Approach 52-Week Low - Market Mover 2021/07/18 14:15:23 Kwhen Finance
Esperion Therapeutics Inc. (ESPR) shares closed today at 0.5% above its 52 week low of $17.36, giving the company a market cap of $491M. The stock is currently down 32.9% year-to-date, down 63.8% over the past 12 months, and up 56.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 49.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 194.2% The company's stock price performance over the past 12 months lags the peer average by -7546.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to email@example.com. © 2020 Kwhen Inc.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs 2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
Comprehensive Report on Heterozygous Familial Hypercholesterolemia Drug Market by 2027 | Daewoong Co Ltd, Esperion Therapeutics Inc, Gemphire Therapeutics Inc 2021/07/15 10:46:32 Tramways Monthly
Heterozygous Familial Hypercholesterolemia Drug Market research report is the new statistical data source added by A2Z Market Research. It uses several approaches for analyzing the data of target market such as primary and secondary research methodologies. It includes investigations based on historical records, current statistics, and futuristic developments. The report gives a thorough overview of the 
NASDAQ Biotech Index is on recovery as short targets join Biogen-led rally 2021/06/09 16:07:14 Seeking Alpha
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings 2021/02/20 14:36:28 Benzinga
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. Bluebird bio Inc (NASDAQ: BLUE ) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS ) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease. The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates. Here are the key catalytic events for the coming week: Conferences: Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26 Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25 Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27 PDUFA Dates The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT ) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations.
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021 2021/02/09 13:00:00 Yahoo Finance
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021. Following the release, company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and business progress. The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing the access code 2689156. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion Therapeutics Esperion is The Lipid Management Company. Our team of lipid experts works to lower bad cholesterol by discovering, developing and commercializing innovative medicines and combinations with established medicines.
Why Novartis, BioVie, Esperion And VBI Are Moving Today 2021/01/15 16:47:09 Benzinga
Esperion Therapeutics (NASDAQ: ESPR ) shares are trading lower … Full story available on Benzinga.com
Why BioLine, Esperion And More Are Moving Today 2020/12/16 16:40:11 Benzinga
Esperion Therapeutics (NASDAQ: ESPR ) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination with NUSTENDI. Esprit Holdings is an international fashion brand whose operations include Retail, Wholesale and Licensing. It produces garments that are sold at its directly managed retail outlets. Esperion Therapeutics shares were trading down 1.77% at $27.67. The stock has a 52-week high of $76.98 and a 52-week low of $23.90. Anika Therapeutics (NASDAQ: ANIK ) shares are trading higher after Barrington Research upgraded the stock from Market … Full story available on Benzinga.com
The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings 2020/11/04 13:21:27 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX )(reacted to positive readout for its stem cell therapy to treat cancer) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(reacted to its quarterly results) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) ( reported strong results for the third quarter) Immunovant Inc (NASDAQ: IMVT ) Scholar Rock Holding Corp (NASDAQ: SRRK ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 3) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aprea Therapeutics Inc (NASDAQ: APRE ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Benitec Biopharma Inc (NASDAQ: BNTC ) Esperion Therapeutics Inc (NASDAQ: ESPR ) (reacted to its quarterly results) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Jaguar Health Inc (NASDAQ: JAGX ) Liminal BioSciences Inc (NASDAQ: LMNL ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Opthea Spon (NASDAQ: OPT ) Silence Therapeutics ADR (NASDAQ: SLN ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires Bristol-Myers Squibb Co (NYSE: BMY ) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire …
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 エスペリオン・セラピュ―ティクス ESPR Esperion Therapeutics Inc.）